Ionis Pharmaceuticals, Inc. Forecast, price target & analysts
Ionis Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Ionis Pharmaceuticals, Inc. Classifications & Recommendation:
Ionis Pharmaceuticals, Inc. Price Target
| Target Price | $71.40 |
| Price | $69.15 |
| Potential |
3.25%
register free of charge
|
| Number of Estimates | 27 |
|
27 Analysts have issued a price target Ionis Pharmaceuticals, Inc. 2026 .
The average Ionis Pharmaceuticals, Inc. target price is $71.40.
This is
3.25%
register free of charge
$100.80
45.77%
register free of charge
$43.43
37.19%
register free of charge
|
|
| A rating was issued by 31 analysts: 23 Analysts recommend Ionis Pharmaceuticals, Inc. to buy, 8 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Ionis Pharmaceuticals, Inc. stock has an average upside potential 2026 of
3.25%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 705.14 | 876.48 |
| 10.48% | 24.30% | |
| EBITDA Margin | -65.68% | -42.55% |
| 61.22% | 35.22% | |
| Net Margin | -64.37% | -47.22% |
| 38.42% | 26.64% |
29 Analysts have issued a sales forecast Ionis Pharmaceuticals, Inc. 2025 . The average Ionis Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
12 Analysts have issued an Ionis Pharmaceuticals, Inc. EBITDA forecast 2025. The average Ionis Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
29 Ionis Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Ionis Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.04 | -2.60 |
| 18.75% | 14.47% | |
| P/E | negative | |
| EV/Sales | 11.40 |
29 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast for earnings per share. The average Ionis Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Ionis Pharmaceuticals, Inc....
Current Ionis Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Sep 26 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Sep 23 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 23 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Sep 23 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Sep 23 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Sep 23 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Sep 04 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Sep 26 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Sep 23 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 23 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Sep 23 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Sep 23 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Sep 23 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Sep 04 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
